A study published in Jan, 2011 in the Journal of the American College of Cardiology found that omega-3 fatty acid (fish oil) supplementation improved heart function, exercise function, and peak oxygen uptake in heart failure patients on standard therapies. This study, led by Mihai Gheorghiade, MD, of Northwestern University in Chicago, added detail to a large, long-term investigation demonstrating that omega-3 fatty acids reduce mortality and cardiovascular hospitalizations in patients with chronic heart failure.
The study randomly assigned 133 heart failure patients to receive either a placebo or the omega-3 fatty acids. (Active treatment consisted of 1-gram capsules containing about 850mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Patients took five capsules daily for the first month, followed by two capsules daily for the rest of the study). After a year, the patients who took the omega-3 fatty acids had a significant improvement in left ventricular ejection fraction (a measure of heart function), whereas those on placebo showed a decline in this measure. Furthermore, while 30% of the patients on placebo required cardiovascular hospitalization during the year, only 6% of those taking the omega-3 supplements were hospitalized due to cardiovascular condition.
In addition to the high-quality Pro Omega Nordic Naturals fish oils supplements, NYBC now stocks Jarrow’s EPA-DHA Balance, which provides another convenient way to match the omega-3 fatty acid supplementation levels used in research studies: